Inspire Investing LLC Grows Stake in The Chemours Company (NYSE:CC)

Inspire Investing LLC boosted its stake in The Chemours Company (NYSE:CC) by 17.4% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 23,799 shares of the specialty chemicals company’s stock after buying an additional 3,523 shares during the quarter. Inspire Investing LLC’s holdings in Chemours were worth $402,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of the company. KBC Group NV lifted its position in shares of Chemours by 19.5% in the third quarter. KBC Group NV now owns 4,468 shares of the specialty chemicals company’s stock valued at $91,000 after acquiring an additional 728 shares in the last quarter. Blue Trust Inc. raised its stake in Chemours by 166.9% in the 3rd quarter. Blue Trust Inc. now owns 1,169 shares of the specialty chemicals company’s stock valued at $26,000 after purchasing an additional 731 shares during the last quarter. GAMMA Investing LLC lifted its holdings in Chemours by 99.7% in the 4th quarter. GAMMA Investing LLC now owns 1,532 shares of the specialty chemicals company’s stock valued at $26,000 after purchasing an additional 765 shares in the last quarter. State of Alaska Department of Revenue boosted its stake in Chemours by 7.3% during the 3rd quarter. State of Alaska Department of Revenue now owns 17,205 shares of the specialty chemicals company’s stock worth $349,000 after purchasing an additional 1,175 shares during the last quarter. Finally, Signaturefd LLC grew its holdings in shares of Chemours by 163.7% during the third quarter. Signaturefd LLC now owns 1,959 shares of the specialty chemicals company’s stock worth $40,000 after buying an additional 1,216 shares in the last quarter. 76.26% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on CC shares. Morgan Stanley lowered their price target on shares of Chemours from $25.00 to $22.00 and set an “equal weight” rating on the stock in a research report on Monday, January 13th. BMO Capital Markets boosted their target price on Chemours from $30.00 to $32.00 and gave the stock an “outperform” rating in a report on Monday, October 7th. Mizuho cut their price target on Chemours from $22.00 to $21.00 and set a “neutral” rating for the company in a report on Tuesday, January 7th. The Goldman Sachs Group dropped their target price on Chemours from $24.00 to $21.00 and set a “neutral” rating for the company in a report on Tuesday, January 7th. Finally, Royal Bank of Canada reiterated an “outperform” rating and set a $25.00 price target on shares of Chemours in a report on Thursday, December 12th. Five analysts have rated the stock with a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat, Chemours has a consensus rating of “Hold” and a consensus target price of $23.75.

Insider Buying and Selling

In related news, SVP Alvenia Scarborough sold 7,500 shares of the stock in a transaction dated Thursday, November 7th. The stock was sold at an average price of $20.64, for a total transaction of $154,800.00. Following the transaction, the senior vice president now owns 16,645 shares of the company’s stock, valued at approximately $343,552.80. This represents a 31.06 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.47% of the stock is currently owned by corporate insiders.

Chemours Stock Performance

Shares of Chemours stock opened at $19.68 on Friday. The firm has a market cap of $2.94 billion, a PE ratio of 39.35 and a beta of 1.83. The company has a quick ratio of 0.92, a current ratio of 1.73 and a debt-to-equity ratio of 6.05. The Chemours Company has a 52 week low of $15.10 and a 52 week high of $32.25. The business’s fifty day simple moving average is $19.18 and its 200-day simple moving average is $19.65.

Chemours (NYSE:CC) last posted its earnings results on Monday, November 4th. The specialty chemicals company reported $0.40 EPS for the quarter, beating analysts’ consensus estimates of $0.32 by $0.08. The company had revenue of $1.50 billion for the quarter, compared to analysts’ expectations of $1.44 billion. Chemours had a net margin of 1.34% and a return on equity of 29.48%. Chemours’s revenue for the quarter was up .9% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.64 earnings per share. Equities analysts forecast that The Chemours Company will post 1.19 earnings per share for the current year.

Chemours Profile

The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure brand for delivering whiteness, brightness, opacity, durability, efficiency, and protection in various of applications, such as architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers used for furniture and building materials, coated paper, and coated paperboard used for packaging.